OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
109
Results
Show all
Save search
Copy query
Show results for
Unknown
(109)
Publication Date
Release Date
2021
(18)
2024
(17)
2022
(14)
2023
(13)
2025
(8)
2011
(7)
2020
(6)
2012
(5)
2019
(3)
2013
(3)
2026
(2)
2018
(2)
2017
(2)
2015
(2)
2008
(2)
2016
(1)
2014
(1)
2010
(1)
2009
(1)
2007
(1)
Previous
page
1 / 11
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
11
Next
page
Sort
by:
Relevance
Page size
10
Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity.
Not available
S-EPMC7180729
|
biostudies-literature
Cite
Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity.
Not available
S-EPMC10729831
|
biostudies-literature
Cite
Incidence of Glaucoma-Related Adverse Events in the First 5 Years After Pediatric Lensectomy.
Not available
S-EPMC9936384
|
biostudies-literature
Cite
Visual Outcomes and Complications After Lensectomy for Traumatic Cataract in Children.
Not available
S-EPMC8209594
|
biostudies-literature
Cite
Dissecting inflammatory complications in critically injured patients by within-patient gene expression changes: a longitudinal clinical genomics study.
Not available
S-EPMC3172280
|
biostudies-literature
Cite
Complications, Visual Acuity, and Refractive Error 3 Years after Secondary Intraocular Lens Implantation for Pediatric Aphakia.
Not available
S-EPMC12165257
|
biostudies-literature
Cite
Visual Acuity and Ophthalmic Outcomes 5 Years After Cataract Surgery Among Children Younger Than 13 Years.
Not available
S-EPMC8832311
|
biostudies-literature
Cite
Refractive Error Change and Overminus Lens Therapy for Childhood Intermittent Exotropia.
Not available
S-EPMC10958385
|
biostudies-literature
Cite
Predictors of Sinonasal Improvement After Highly Effective Modulator Therapy in Adults with Cystic Fibrosis.
Not available
S-EPMC11305934
|
biostudies-literature
Cite
Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.
Not available
S-EPMC9509410
|
biostudies-literature
Cite
Previous
page
1 / 11
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
11
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets